Biopharmx Corporation (NYSEMKT:BPMX) Can’t Be More Risky. Short Interest Increased

June 19, 2017 - By Kurt Siggers

 Biopharmx Corporation (NYSEMKT:BPMX) Can't Be More Risky. Short Interest Increased

The stock of Biopharmx Corporation (NYSEMKT:BPMX) registered an increase of 27.15% in short interest. BPMX’s total short interest was 4.69M shares in June as published by FINRA. Its up 27.15% from 3.69M shares, reported previously. With 3.28M shares average volume, it will take short sellers 1 days to cover their BPMX’s short positions. The short interest to Biopharmx Corporation’s float is 11.71%.

About 67,316 shares traded. Biopharmx Corp (NYSEMKT:BPMX) has declined 5.75% since June 19, 2016 and is downtrending. It has underperformed by 22.45% the S&P500.

BioPharmX Corporation is a specialty pharmaceutical company. The company has market cap of $34.39 million. The Firm is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter products that address markets in women’s health and dermatology. It currently has negative earnings. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Biopharmx Corp (NYSEMKT:BPMX) Ratings Coverage

Among 5 analysts covering BioPharmX Corporation (NYSEMKT:BPMX), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. BioPharmX Corporation had 5 analyst reports since September 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Friday, May 5. The rating was upgraded by ValuEngine on Thursday, May 25 to “Sell”. The stock of Biopharmx Corp (NYSEMKT:BPMX) earned “Buy” rating by H.C. Wainwright on Friday, May 5. The firm has “Buy” rating given on Friday, September 4 by Sterne Agee CRT. Maxim Group maintained Biopharmx Corp (NYSEMKT:BPMX) on Friday, May 5 with “Buy” rating.

More important recent Biopharmx Corp (NYSEMKT:BPMX) news were published by: which released: “BioPharmX to Report First Quarter Financial Results” on June 07, 2017, also published article titled: “BioPharmX Invited to Present at World Preclinical Congress”, published: “BioPharmX Has A Major Upcoming Catalyst” on March 27, 2017. More interesting news about Biopharmx Corp (NYSEMKT:BPMX) was released by: and their article: “BioPharmX Reports First Quarter 2018 Financial Results” with publication date: June 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.